Lyra Therapeutics Q3 net loss narrows

Reuters

Nov 13

<a href="https://laohu8.com/S/LYRA">Lyra Therapeutics</a> Q3 net loss narrows

Overview

Lyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last year
Company plans new Phase 3 trial for LYR-210, aiming for NDA submission
Cash reserves expected to fund operations into Q3 2026

Outlook

Lyra plans new Phase 3 trial for LYR-210, targeting NDA submission
Company anticipates cash reserves to fund operations until Q3 2026

Result Drivers

R&D EXPENSES - Decrease in R&D expenses due to completion of ENLIGHTEN 2 trial and workforce reduction
G&A EXPENSES - Reduction in general and administrative expenses due to lower employee costs and operational savings

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration Revenue		$25,000
Q3 EPS		-$3.38
Q3 Net Income		-$5.98 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Lyra Therapeutics Inc is $23.00, about 81.6% above its November 11 closing price of $4.24

Press Release: ID:nGNX13nXTP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2583833965"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583833965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583833965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583833965","market":"us","top_or_hot":-1,"title":"Lyra Therapeutics Q3 net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title> <a href=\"https://laohu8.com/S/LYRA\">Lyra Therapeutics</a> Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Lyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last year</p></li><li><p>Company plans new Phase 3 trial for LYR-210, aiming for NDA submission</p></li><li><p>Cash reserves expected to fund operations into Q3 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Lyra plans new Phase 3 trial for LYR-210, targeting NDA submission</p></li><li><p>Company anticipates cash reserves to fund operations until Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Decrease in R&amp;D expenses due to completion of ENLIGHTEN 2 trial and workforce reduction</p></li><li><p>G&amp;A EXPENSES - Reduction in general and administrative expenses due to lower employee costs and operational savings</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$25,000</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$3.38</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$5.98 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Lyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $23.00, about 81.6% above its November 11 closing price of $4.24</p></li></ul><p>Press Release: <span>ID:nGNX13nXTP</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lyra Therapeutics Q3 net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLyra Therapeutics Q3 net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title> <a href=\"https://laohu8.com/S/LYRA\">Lyra Therapeutics</a> Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Lyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last year</p></li><li><p>Company plans new Phase 3 trial for LYR-210, aiming for NDA submission</p></li><li><p>Cash reserves expected to fund operations into Q3 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Lyra plans new Phase 3 trial for LYR-210, targeting NDA submission</p></li><li><p>Company anticipates cash reserves to fund operations until Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Decrease in R&amp;D expenses due to completion of ENLIGHTEN 2 trial and workforce reduction</p></li><li><p>G&amp;A EXPENSES - Reduction in general and administrative expenses due to lower employee costs and operational savings</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$25,000</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$3.38</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$5.98 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Lyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $23.00, about 81.6% above its November 11 closing price of $4.24</p></li></ul><p>Press Release: <span>ID:nGNX13nXTP</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LYRA","symbol_name":"Lyra Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO12X:1","article_id":"2583833965","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583833965","pubTimestamp":1762982289,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lyra Therapeutics Q3 net loss narrowsOverviewLyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last yearCompany plans new Phase 3 trial for LYR-210, aiming for NDA submissionCash reserves","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LYRA":"Lyra Therapeutics","BK4007":"制药"},"translate_title":"Lyra Therapeutics第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LYRA":0.9},"content_text":"Lyra Therapeutics Q3 net loss narrowsOverviewLyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last yearCompany plans new Phase 3 trial for LYR-210, aiming for NDA submissionCash reserves expected to fund operations into Q3 2026OutlookLyra plans new Phase 3 trial for LYR-210, targeting NDA submissionCompany anticipates cash reserves to fund operations until Q3 2026Result DriversR&D EXPENSES - Decrease in R&D expenses due to completion of ENLIGHTEN 2 trial and workforce reductionG&A EXPENSES - Reduction in general and administrative expenses due to lower employee costs and operational savingsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration Revenue$25,000Q3 EPS-$3.38Q3 Net Income-$5.98 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Lyra Therapeutics Inc is $23.00, about 81.6% above its November 11 closing price of $4.24Press Release: ID:nGNX13nXTPFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}